Revvity RVTY Life Sciences — Segment Selling, general and administrative expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept revv:SegmentSellingGeneralAndAdministrativeExpenses.
The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revvity's life sciences — segment selling, general and administrative expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's life sciences — segment selling, general and administrative expenses?
- Revvity (RVTY) reported life sciences — segment selling, general and administrative expenses of $94.67M in Q1 2026.
- How has Revvity's life sciences — segment selling, general and administrative expenses changed year-over-year?
- Revvity's life sciences — segment selling, general and administrative expenses increased by 8.7% year-over-year, from $87.09M to $94.67M.
- What is the long-term trend for Revvity's life sciences — segment selling, general and administrative expenses?
- Over 3 years (2022 to 2025), Revvity's life sciences — segment selling, general and administrative expenses has grown at a 6.8% compound annual growth rate (CAGR), from $282.98M to $344.52M.
- What does life sciences — segment selling, general and administrative expenses mean?
- Operating costs for sales, marketing, and administration in the Life Sciences segment.
- How do you interpret life sciences — segment selling, general and administrative expenses?
- High spending may be necessary for growth, but excessive levels relative to revenue indicate poor operational leverage.
- How does life sciences — segment selling, general and administrative expenses compare across companies?
- Standard 'SG&A' metric used to evaluate operational overhead across public companies.